Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: A single center experience

Rheumatology International

Volumn 33, Issue 6, 2013, Pages 1495-1504

  Braun Moscovici, Yolanda ^a,d   Butbul Aviel, Yonatan ^b,d   Guralnik, Ludmila ^c,d   Toledano, Kochava ^a,d   Markovits, Doron ^a,d   Rozin, Alexander ^a,d   Nahir, Menahem A ^a,d   Balbir Gurman, Alexandra ^a,d  

^a B Shine Rheumatology Unit   (Israel)

^b MEYER CHILDREN S HOSPITAL   (Israel)

^c The Diagnostic Imaging Department   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti phospholipid syndrome; Pulmonary hemorrhage; Rituximab; Vasculitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; ILOPROST; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL ARTICLE; EMPYEMA; ENDOCARDITIS; FEMALE; HEART INJURY; HEPATITIS B; HUMAN; KAPOSI SARCOMA; KIDNEY INJURY; LUNG HEMORRHAGE; LUNG INJURY; MALE; NERVOUS SYSTEM INJURY; NEUROPATHY; PLASMAPHERESIS; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; VASCULITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84878705453     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2587-x     Document Type: Article

References (32)

1. McDonald V, Leandro M (2009) Rituximab in non-haematological disorders of adults and its mode of action. BJH 146:233-246
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
3. Pescovitz MD (2006) Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859-866
4. Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42(3):421-430
5. Lauque D, Cadranel J, Lazor R et al (2000) Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 79(4):222-233
6. Schwarz MI, Brown KK (2000) Small vessel vasculitis of the lung. Thorax 55(6):502-510
7. Lara AR, Schwarz MI (2010) Diffuse alveolar hemorrhage. Chest 137(5):1164-1171
8. Pottier V, Pierrot M, Subra JF, Mercat A, Kouatchet A, Parrot A, Augusto JF. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011 May; 20(6):656-659. Epub 2011 Feb 18
9. Narshi CB, Haider S, Ford CM, Isenberg DA, Giles IP (2010) Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford) 49(2):392-394
10. Pinto LF, Candia L, Garcia P, Marín JI, Pachón I, Espinoza LR, Marquez J (2009) Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab). Respiration 78(1):106-109
11. Nellessen CM, Pöge U, Brensing KA, Sauerbruch T, Klehr HU, Rabe C (2008) Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: a case report. Nephrol Dial Transplant 23(1):385-386
12. Arad U, Balbir-Gurman A, Doenyas-Barak K, Amit-Vazina M, Caspi D, Elkayam O (2011) Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 41(2):223-229
13. Elazary AS, Klahr P, Hershko A, Dranitzki Z, Rubinow A, Naparstek Y (2012) Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome. Lupus 21(4):438-440
14. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355-357
15. Manner H, Jung B, Tonassi L et al (2008) Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 335:394-397
16. van Wissen S, Bastiaansen BMJ, Stroobants AK et al (2008) Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour - a case report. Lupus 17:586-590
17. Asherson RA, Espinosa G, Menahem S et al (2008) Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 37:377-382
18. Nageswara Rao AA, Arteaga GM, Reed AM, Gloor JM, Rodriguez V (2009) Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 52:536-538
19. Jamoussi SK, Zaghdoudi I, Ben Dhaou B et al (2009) Catastrophic antiphospholipid syndrome and rituximab: a new report. Tunis Med 87:699-702
20. Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, Lirola-Cruz J, Neth O (2010) Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 125:e1523-e1528
21. Espinosa G, Berman H, Cervera R (2011) Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 10(11):664-668
22. Hennigan S, Channick RN, Silverman GJ (2008) Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 17(8):754-756
23. Lui NL, Thumboo J, Fong KY (2009) A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy. Int J Rheum Dis 12(4):366-369
24. Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28(4):468-476
25. De Stefano R, Frati E, Nargi F, Menza L (2011) Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF- α therapy. Clin Exp Rheumatol 29(4):752-753
26. Child N, O'Carroll M, Berkahn L (2012) Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. Intern Med J 42(3):e12-e14
27. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51(4):653-662
28. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT (2009) Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 11(4):R131
29. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheumatism 56(3):772-778
30. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58:2993-2999
31. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D (2011) Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 63(3):603-608
32. Cambridge G, Leandro MJ, Teodorescu M et al (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612-3622